Tirzix 5 mg

Generic Name: Tirzepatide
Strength: 5 mg
Manufacturer: Beacon Pharmaceuticals Ltd.
Form: Subcutaneous Injection (Prefilled Pen or Vial)

Description:

Tirzix 5 mg contains Tirzepatide, a novel dual agonist of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is used as a once-weekly injectable medication primarily indicated for type 2 diabetes mellitus and shows promising results in weight management and metabolic control.

Tirzix offers a unique mechanism that enhances insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite — contributing to better glycemic control and significant weight loss benefits.

Indications:

• Type 2 Diabetes Mellitus (as adjunct to diet and exercise)

• Obesity and overweight management (off-label, under clinical guidance)

Dosage & Administration:

• Starting dose: 2.5 mg once weekly (typically increased every 4 weeks)

• Maintenance dose: 5 mg to 15 mg once weekly, based on patient tolerance and therapeutic goal

• Administered subcutaneously in the abdomen, thigh, or upper arm

Pharmacology:

Tirzepatide mimics the action of GIP and GLP-1, stimulating insulin release and improving glycemic control. Its dual agonism leads to enhanced metabolic outcomes compared to traditional GLP-1 therapies.

Side Effects:

• Nausea, vomiting, diarrhea

• Decreased appetite

• Injection site reactions

• Hypoglycemia (especially when used with insulin or sulfonylureas)

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

• Hypersensitivity to tirzepatide or excipients

Storage Conditions:

• Store in a refrigerator (2°C to 8°C)

• Do not freeze

• Protect from light

Therapeutic Class:

GLP-1 Receptor Agonist / Dual Incretin Receptor Agonist